p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy

Journal of Urology

Volumn 162, Issue 1, 1999, Pages 69-73

  Pfister, Christian ^a,b   Flaman, Jean Michel ^b   Dunet, Frederick ^b   Grise, Philippe ^b   Frebourg, Thierry ^b  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b IFRMP 23   (France)

Author keywords

Bladder neoplasms; Genes, p53; Mycobacterium bovis

Indexed keywords

BCG VACCINE; GENE PRODUCT; PROTEIN BAX; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER SURGERY; DRUG RESPONSE; GENE INACTIVATION; GENE MUTATION; HUMAN; HUMAN TISSUE; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; TRANSACTIVATION;

EID: 0032825985     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199907000-00017     Document Type: Article

References (37)

1. Beroud, C., Verdier, F. and Soussi, T.: p53 gene mutation: software and database. Nucleic Acids Res., 24: 147, 1996.
2. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, P. J., Chen, S. C., Nichols, P. W., Skinner, D. G., Jones, P. A. and Cote, R. J.: Accumulation of nuclear p53 and tumor progression in bladder cancer. New Engl. J. Med., 331: 1259, 1994.
3. Gardiner, R. A., Walsh, M. D., Allen, V., Rahman, S., Samaratunga, M. L., Seymour, G. J. and Lavin, M. F.: Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression. Brit. J. Urol., 73: 526, 1994.
4. Ishioka, C., Frebourg, T., Yan, Y. X., Vidal, M., Friend, S. H., Schmidt, S. and Iggo, R.: Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat. Genet., 5: 124, 1993.
5. Flaman, J. M., Frebourg, T., Moreau, V., Charbonnier, F., Martin, C., Chappuis, P., Sappino, A. P., Limacher, J. M., Bron, L., Benhattar, J., Tada, M., Van Meir, E. G., Estreicher, A. and Iggo, R. D.: A simple p53 functional assay for screening cell lines, blood and tumors. Proc. Natl. Acad. Sci., 92: 3963, 1995.
6. Ludwig, R. L., Bates, S. and Vousden, K. H.: Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell. Biol., 16: 4952, 1996.
7. Gottlieb, T. M. and Oren, M.: p53 in growth control and neoplasia. Biochim. Biophys. Acta, 1287: 77, 1996.
8. Braithwaite, K. L., Mellon, J. K. and Neal, D. E.: WAF1 expression in transitional cell carcinoma (TCC) of the bladder: inverse relationship to p53 accumulation and association with good prognosis. Proc. Amer. Assn. Cancer Res., p. 3534, 1997.
9. Waldman, T., Zhang, Y., Dillehay, L., Yu, J., Kinzler, K., Vogelstein, B. and Williams, J.: Cell-cycle arrest versus cell death in cancer therapy. Nat. Med., 3: 1034, 1997.
10. Pfister, C., Flaman, J. M., Grise, P. and Frebourg, T.: Detection of p53 mutations in bladder tumors with a functional assay in yeast. Brit. J. Urol., 80: 235, 1997.
11. Jakse, G., Loidl, W., Seeber, G. and Hofstädter, F.: Stage T1, grade 3 transitional carcinoma of the bladder: an unfavorable tumor? J. Urol., 137: 39, 1987.
12. Lamm, D. L.: Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J. Urol., 134: 40, 1985.
13. Flaman, J. M., Robert, V., Lenglet, S., Moreau, V., Iggo, R. and Frebourg, T.: Identification of human p53 mutations with differential effects on the Bax and p21 promoters using functional assays in yeast. Oncogene, 16: 1369, 1998.
14. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B.: WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817, 1993.
15. Miyashita, T. and Reed, J. C.: Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene. Cell, 80: 293, 1995.
16. Waridel, F., Estreicher, A., Bron, L., Flaman, J. M., Fontolliet, C., Monnier, P., Frebourg, T. and Iggo, R.: Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene, 14: 163, 1997.
17. Herr, H. W., Wartinger, D., Fair, W. R. and Oettgen, H. F.: Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10 year followup. J. Urol., 147: 1020, 1992.
18. Hudson, L. A.: When intravesical measures fail. Indications for cystectomy in superficial disease. Urol. Clin. N. Amer., 19: 601, 1992.
19. Vogelstein, B. and Kinzler, K. W.: p53 function and dysfunction. Cell, 70: 523, 1992.
20. Têtu, B., Fradet, Y., Allard, P., Veilleux, C., Roberge, N. and Bernard, P.: Prevalence and clinical significance of HER-2/ neu, p53 and Rb expression in primary superficial bladder cancer. J. Urol., 155: 1784, 1996.
21. Casetta, G., Gontero, P., Russo, R., Pacchioni, D. and Tizzani, A.: p53 expression compared with other prognostic factors in OMS grade-1 stage-Ta transitional cell carcinoma of the bladder. Eur. Urol., 32: 229, 1997.
22. Mosch, H., Sauter, G., Mitatsch, M. J., Gudat, F., Epper, R. and Waldman, F. M.: p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum. Path., 25: 1346, 1994.
23. Sarkis, A., Dalbagni, G., Cordon-Cardo, C., Zhang, Z. F., Sheinfeld, J., Fair, W. R., Herr, H. W. and Reuter, V. E.: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl. Cancer Inst., 85: 53, 1993.
24. Sarkis, A. S., Dalgani, G., Cordon-Cardo, C., Melamed, J., Zhang, Z. F., Sheinfeld, J., Fair, W. R., Herr, H. W. and Reuter, V. E.: Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J. Urol., 152: 388, 1994.
25. Raitanen, M. P., Tammela, T. L., Kallioinen, M. and Isola, J.: p53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer. J. Urol., 157: 1250, 1997.
26. Gregers, G. H., Horn, T. and Steven, K.: The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J. Urol., 159: 91, 1998.
27. Malmström, P. U., Busch, C. and Norlen, B. J.: Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand. J. Urol. Nephrol., 21: 185, 1987.
28. Kaye, K. W. and Lange, P. H.: Mode of presentation of invasive bladder cancer: reassessment of the problem. J. Urol., 128: 31, 1982.
29. Lacombe, L., Dalbagni, G., Zhang, Z. F., Cordon-Cardo, C., Fair, W. R., Herr, H. W. and Reuter, V. E.: Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome. J. Clin. Oncol., 14: 2646, 1996.
30. Ick, K., Schultz, M., Stout, P. and Fan, K.: Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guérin treatment. Urology, 49: 541, 1997.
31. Ovesen, H., Horn, T. and Steven, K.: Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation. J. Urol., 157: 1655, 1997.
32. Pages, F., Flam, T. A., Vieillefond, A., Molinie, V., Abeille, X., Lazar, V., Bressac-de Paillerets, B., Mosseri, V., Zerbib, M., Fridman, W. H., Debre, B. and Thiounn, N.: p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors. J. Urol., 159: 1079, 1998.
33. Lebret, T., Becette, V., Barbagelatta, M., Hervé, J.-M., Gaudez, F., Barré, P., Lugagne, P.-M. and Botto, H.: Correlation between p53 overexpression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer. J. Urol., 159: 788, 1998.
34. Caliskan, M., Türkeri, L. N., Mansuroglu, B., Toktas, G., Aksoy, B., Unlüer, E. and Akdas, A.: Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer. Brit. J. Urol., 79: 373, 1997.
35. Marx, J.: How p53 suppresses cell growth. Science, 262: 1644, 1993.
36. Lacombe, L., Orlow, I. and Silver, D.: Analysis of p21WAF1/CIP1 in primary bladder tumors. Oncol. Res., 8: 409, 1994.
37. Cote, R., Esrig, D., Groshen, S., Jones, P. and Skinner, D. G.: p53 and treatment of bladder cancer (Letter to the Editor). Nature, 385: 123, 1997.